Get the Stockscreener App
7.45
1.36%
0.10
After Hours:
7.59
0.14
+1.88%
Puma Biotechnology Inc stock is traded at $7.45, with a volume of 484.46K.
It is up +1.36% in the last 24 hours and up +8.13% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$7.35
Open:
$7.44
24h Volume:
484.46K
Relative Volume:
1.33
Market Cap:
$379.14M
Revenue:
$228.37M
Net Income/Loss:
$31.11M
P/E Ratio:
12.20
EPS:
0.6108
Net Cash Flow:
$41.73M
1W Performance:
-0.40%
1M Performance:
+8.13%
6M Performance:
+52.04%
1Y Performance:
+150.00%
1-Day Range:
$7.395
$7.6999
1-Week Range:
$7.11
$7.70
52-Week Range:
$2.85
$7.8983
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
7.45 | 374.05M | 228.37M | 31.11M | 41.73M | 0.6108 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Six new Puma hires get stock awards covering 59,750 shares - Stock Titan
MSN Money - MSN
Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday - MarketBeat
PBYI Stock Price, Quote & Chart | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Puma Biotechnology | 10-Q: Q2 2025 Earnings Report - Moomoo
CEO warrant extension and pay vote at Puma Biotechnology (NASDAQ: PBYI) meeting - Stock Titan
[ARS] PUMA BIOTECHNOLOGY, INC. SEC Filing - Stock Titan
Puma Biotechnology (PBYI) Stock Price Alert (Technical Strength) 2026-04-27Investment Picks - Newser
Puma Biotechnology stock declines more than 9% in a month: Here's why - MSN
Press Release: Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results - 富途牛牛
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results - BioSpace
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Ritholtz Wealth Management Boosts Stake in Puma Biotechnology - National Today
Puma Biotechnology, Inc. $PBYI Shares Acquired by Ritholtz Wealth Management - MarketBeat
Is Puma Biotechnology (PBYI) Stock Attractive Now | Price at $7.72, Down 0.96%Sentiment Analysis - Cổng thông tin điện tử tỉnh Lào Cai
What Do Analysts Think About Puma Biotechnology (PBYI)? - MSN
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Puma Biotechnology Stock Surges Past 200-Day Average - National Today
Puma Biotechnology (NASDAQ: PBYI) seeks votes to extend CEO warrant, elect directors - Stock Titan
Can Puma Biotechnology Inc sustain its profitabilityWeekly Stock Analysis & Real-Time Market Trend Scan - baoquankhu1.vn
PBYI PE Ratio & Valuation, Is PBYI Overvalued - Intellectia AI
Investor Mood: Is Puma Biotechnology Inc undervalued by DCF analysisWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 - BioSpace
PBYI Stock Analysis: Puma Biotechnology Inc holds 6.9 level after 2.07 pct gain - Cổng thông tin điện tử tỉnh Tây Ninh
Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Pharma News: Is Puma Biotechnology Inc a momentum stockAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Recap Report: What is Puma Biotechnology Incs 5 year growth outlook2026 Technicals & Low Risk Growth Stock Ideas - baoquankhu1.vn
Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially - Investing.com
Earnings call transcript: Puma Biotechnology Inc. reports strong Q4 2025 results - in.investing.com
Vanguard disaggregates holdings; Puma Biotechnology (PBYI) shows 0 shares reported - stocktitan.net
Forecast Cut: Is Puma Biotechnology Inc a momentum stockPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
Rate Hike: Can Puma Biotechnology Inc be the next market leaderPortfolio Update Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy - MarketBeat
Shorts Report: Is Puma Biotechnology Inc undervalued by DCF analysis2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):